Citations

Clear

3138 citation(s) found for "Smith, AM".

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
Hilton, Laura K. , Collinge, Brett , Alduaij, Waleed , Shaalan, Haya, Weng, Andrew P. , Cruz, Manuela Martins , Slack, Graham W. , Farinha, Pedro , Miyata‐Takata, Tomoko , Boyle, Merrill, Meissner, Barbara , Cook, James R. , Ondrejka, Sarah L. , Ott, German , Rosenwald, Andreas , Greiner, Timothy C. , Weisenburger, Dennis D. , Chan, Wing C. , Beiske, Klaus, Fu, Kai , Delabie, Jan , Pittaluga, Stafania, Iqbal, Javeed , Wright, George, Staudt, Louis M. , Wright, George W. , Alduaij, Waleed , Weng, Andrew P , Farinha, Pedro , Boyle, Merrill , Cook, James R , Ondrejka, Sarah , Campo, Elías , Amador, Catalina , Greiner, Timothy C , Inghirami, Giorgio , Jaffe, Elaine S , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J , Mungall, Andrew J , Feldman, Andrew L , Steidl, Christian , Morin, Ryan D , Scott, David W , Iqbal, Javeed , Wright, George , Hilton, Laura K , Ben‐Neriah, Susana , Cruz, Manuela, Campo, Elı́as , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Jaffe, Elaine S. , Pittaluga, Stefania , Sehn, Laurie H. , Savage, Kerry J. , Mungall, Andrew J. , Feldman, Andrew L. , Steidl, Christian , Rimsza, Lisa M. , Scott, David W.

Mayo Clinic

Blood | May 3, 2024 | Volume: 144 | Issue: 5 | Pages: 525-540

10.1182/blood.2024024251 | PMID 38701426 Get It

Abstract Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double hit”; HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of and mechanisms driving IG vs non-IG MYC rearrangements have not been elucidated. Here, we used custom targeted capture and/or whole-genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, although BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYC::IGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because 1 IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B-cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.
Moderate Aortic Valve Stenosis Is Associated With Increased Mortality Rate and Lifetime Loss: Systematic Review and Meta‐Analysis of Reconstructed Time‐to‐Event Data of 409 680 Patients
Jacquemyn, Xander , Strom, Jordan B. , Strange, Geoff , Playford, David , Stewart, Simon , Kutty, Shelby , Bhatt, Deepak L. , Bleiziffer, Sabine , Pellikka, Patricia A. , Pîbarot, Philippe , Grubb, Kendra J , Pellikka, Patricia A , Clavel, Marie-Annick , Pibarot, Phillippe , Mentias, Amgad , Serna-Gallegos, Derek , Sá, Michel Pompeu , Sultan, Ibrahim , Strom, Jordan B , Bhatt, Deepak L , Clavel, Marie‐Annick , Sá, Michel Pompeu , Sultan, Ibrahim

Mayo Clinic

Journal of the American Heart Association | May 3, 2024 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/jaha.123.033872 | PMID 38700000 Get It

Background The mortality risk attributable to moderate aortic stenosis (AS) remains incompletely characterized and has historically been underestimated. We aim to evaluate the association between moderate AS and all‐cause death, comparing it with no/mild AS (in a general referral population and in patients with heart failure with reduced ejection fraction). Methods and Results A systematic review and pooled meta‐analysis of Kaplan–Meier‐derived reconstructed time‐to‐event data of studies published by June 2023 was conducted to evaluate survival outcomes among patients with moderate AS in comparison with individuals with no/mild AS. Ten studies were included, encompassing a total of 409 680 patients (11 527 with moderate AS and 398 153 with no/mild AS). In the overall population, the 15‐year overall survival rate was 23.3% (95% CI, 19.1%–28.3%) in patients with moderate AS and 58.9% (95% CI, 58.1%–59.7%) in patients with no/mild aortic stenosis (hazard ratio [HR], 2.55 [95% CI, 2.46–2.64]; P <0.001). In patients with heart failure with reduced ejection fraction, the 10‐year overall survival rate was 15.5% (95% CI, 10.0%–24.0%) in patients with moderate AS and 37.3% (95% CI, 36.2%–38.5%) in patients with no/mild AS (HR, 1.83 [95% CI, 1.69–2.0]; P <0.001). In both populations (overall and heart failure with reduced ejection fraction), these differences correspond to significant lifetime loss associated with moderate AS during follow‐up (4.4 years, P <0.001; and 1.9 years, P <0.001, respectively). A consistent pattern of elevated mortality rate associated with moderate AS in sensitivity analyses of matched studies was observed. Conclusions Moderate AS was associated with higher risk of death and lifetime loss compared with patients with no/mild AS.
Abstract PO2-20-01: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer (TBCRC 062)
Parsons, Heather A. , Ruddy, Kathryn J. , Morganti, Stefania , Attaya, Victoria , Kallfelz, Eliza , DeMeo, Michelle K. , LaScala, Jamie, Mertz, Shirley, Pollastro, Teri, Spears, Patricia A. , Dang, Chau T. , Gwin, William R. , O’Sullivan, Ciara C. , Walsh, Elaine , Storniolo, Anna Maria , Tolaney, Sara M. , Tayob, Nabihah , Rimawi, Mothaffar F. , Krop, Ian E. , Rimawi, Mothaffar , Smith, Karen L. , Brufsky, Adam , Dent, Susan , Elkhanany, Ahmed , Miller, Kathy D. , Nunnery, Sara E. , Walsh, Elaine, Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U.

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO2-20-01-PO2-20-01

10.1158/1538-7445.sabcs23-po2-20-01 Get It

Abstract BACKGROUND: Anti-HER2 therapies have transformed the trajectory for patients with HER2-positive (HER2+) MBC. A subset of patients with HER2+ MBC do exceptionally well and remain on maintenance anti-HER2 therapy for many years. However, current therapy is non-curative and patients are treated indefinitely. While these therapies often are well-tolerated, they may cause significant toxicities, are expensive, and typically require frequent infusion and provider visits. Case reports and retrospective series demonstrate that some patients may do well after stopping anti-HER2 treatment. We currently lack prospective data on the likelihood of clinical impact of successful treatment discontinuation, outcomes among patients who progress and restart HER2-directed therapy, and tools to predict who may safely stop therapy. In this study, we will enroll pts with an exceptional response to anti-HER2 therapy. Pts may elect to either continue or stop anti-HER2 therapy and will be followed clinically and radiographically on a protocol-specified schedule. Considering the central role of patients in choosing the study intervention arm, and the unique nature of stopping therapy as a treatment intervention, patient advocates have been deeply involved in the study design to ensure patient concerns are being heard and addressed. We will retrospectively assess minimal residual disease (MRD), measured in plasma, as a biomarker of ongoing response, in a step toward shifting the treatment paradigm for pts with HER2+ MBC. METHODS: STOP-HER2 is a prospective, non-randomized, phase II, multicenter study of either continuation (cohort 1) or cessation (cohort 2) of anti-HER2 therapy in exceptional responders with HER2+ MBC. Eligible patients must have biopsy-proven HER2+ MBC by ASCO/CAP guidelines and must have been receiving first-line anti-HER2 therapy for MBC for at least 3 years without evidence of progressive disease (PD) as determined by the treating investigator. Patients with prior brain-only PD or oligo-PD outside the brain are eligible at least 2 years after local treatment to the central nervous system (CNS) and in absence of subsequent PD. Up to fifty-two participants will be enrolled into cohort 2, and an additional thirty participants enrolled into the cohort 1, at 10 US sites within the Translational Breast Cancer Research Consortium. Co-primary endpoints are the 1-year progression-free survival (PFS) in cohorts 2 and 1, separately. Secondary endpoints include the clinical benefit rate upon re-initiation of anti-HER2 therapy for patients in cohort 2 experiencing PD after treatment discontinuation; and 3-year overall survival in both cohorts. Correlative endpoints include MRD status at baseline and the correlation between MRD dynamics and outcomes. Patient-reported outcomes will be collected and analyzed, including quality of life, illness intrusiveness, financial toxicity, anxiety, and decision regret. The study will use a two-stage design to assess the primary objective of estimating the rate of participants who are free of progression at one year after discontinuing anti-HER2 therapy. If 50% or less are free of progression at one year, stopping HER2 therapy would not be considered a viable treatment plan (null hypothesis). The study is designed to have 80% power to reject the null hypothesis at the 10% type I error rate when 68% of exceptional responders are free of progression at one year after stopping HER2 therapy. STOP-HER2 began enrollment in Q2 2023 (NCT05721248). Citation Format: Heather Parsons, Kathryn Ruddy, Stefania Morganti, Karen Smith, Victoria Attaya, Eliza Kallfelz, Michelle DeMeo, Jamie LaScala, Shirley Mertz, Teri Pollastro, Patricia Spears, Adam Brufsky, Chau Dang, Susan Dent, Ahmed Elkhanany, WIlliam Gwin, Ciara O'Sullivan, Kathy Miller, Sara Nunnery, Elaine Walsh, Anna Maria Storniolo, Sara Tolaney, Nabihah Tayob, Antonio Wolff, Eric Winer, Mothaffar Rimawi, Ian Krop, Nancy Lin. The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer (TBCRC 062) [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-20-01.
Abstract PO2-12-09: Insomnia, Pain, Anxiety, Distress, Fatigue, and Functional Impairment in Patients with Breast Cancer
Ruddy, Kathryn J. , Grzegorczyk, Veronica , Pachman, Deirdre R. , Smith, Deanne, O’Sullivan, Ciara C. , Ehlers, Shawna L. , Rahman, Parvez, Mitchell, Sandra A , Liu, Bolun , Herrin, Jeph , Cheville, Andrea

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO2-12-09-PO2-12-09

10.1158/1538-7445.sabcs23-po2-12-09 Get It

Abstract Background: SPPADE symptoms (Sleep disturbance, Pain, Physical function impairment, Anxiety, Depression/distress, and Energy deficits/fatigue) may result from cancer and its treatment. The aim of this analysis was to characterize SPPADE symptoms in patients with breast cancer. Methods. SPPADE data were drawn from the Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) study, a stepped-wedge pragmatic cluster-randomized trial designed to evaluate a symptom management intervention in routine practice (NCT03892967). Symptom severity was measured on a 0-10 scale via a survey administered by patient portal, in-clinic tablet, or interactive voice response system (by phone) prior to, during, or soon after an outpatient oncology encounter. Scores of 4-6 were categorized as “moderate” and ≥7 as “severe.” In this analysis, only the data from each patient’s initial survey were included. Results. A total of 9,651 patients with breast cancer completed an initial E2C2 survey between March 2019 and January 2023. The proportion of patients with moderate or severe SPPADE symptoms were as follows: 22% moderate and 10% severe for insomnia; 18% moderate and 7% severe for pain; 17% moderate and 7% severe for anxiety; 15% moderate and 5% severe for emotional distress; 25% moderate and 12% severe for fatigue; and 22% moderate and 8% severe for impaired physical function. Table 1 presents score means and standard deviations by demographic subgroup. Conclusions. SPPADE symptoms are common in patients with breast cancer. These observations warrant routine implementation of symptom surveillance and management in breast oncology. Funding acknowledgement: The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium is a Cancer Moonshot Research Initiative under the authorization of the 2016 United States 21st Century Cures Act. This research was supported by the National Cancer Institute of the NIH, UM1CA233033 (Mayo Clinic, Rochester, MN). Insomnia, Pain, Anxiety, Distress, Fatigue, and Functional Impairment in Patients with Breast Cancer Citation Format: Kathryn Ruddy, Veronica Grzegorczyk, Deirdre Pachman, Sandra Mitchell, Bolun Liu, Deanne Smith, Ciara O'Sullivan, Shawna Ehlers, Jeph Herrin, Parvez Rahman, Andrea Cheville. Insomnia, Pain, Anxiety, Distress, Fatigue, and Functional Impairment in Patients with Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-09.
Longitudinal Progression of CT Emphysema Subtypes Using Density-based and Hidden Markov Measure Field-based Thresholds: The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
Wysoczanski, Artur , Bowler, R.P., Cooper, Christopher B. , Menchaca, Martha , Ortega, Victor E. , Paine, Robert , Woodruff, Prescott G. , Laine, Andrew F. , Angelini, Elsa D. , Hermann, E.A. , Dransfield, Mark T. , Han, MeiLan King , Hoffman, Eric A. , Krishnan, Jerry A , Menchaca, M.G., Ohar, Jill , Smith, Benjamin M. , Sun, Yuan‐Wan , Barr, R. Graham

Mayo Clinic

D15. MACHINE LEARNING AND LARGE COHORT STUDIES TO UNDERSTAND EXPOSURE-RELATED LUNG DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6928-A6928

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6928 Get It

Camlipixant Reduces Burden of Cough-related Urinary Incontinence in Patients With Refractory Chronic Cough in Post-hoc Analysis of A Phase 2b Trial
Taliercio, Rachel M., Birring, Surinder S. , Lanouette, S., Yang, Ronghua , Garin, Margaret , Bonuccelli, Catherine M., Iyer, Vivek , Dicpinigaitis, Peter V. , Smith, John A. , Yang, R.

Mayo Clinic

D25. EMERGING RESEARCH IN COUGH, CYSTIC FIBROSIS AND BRONCHIECTASIS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7083-A7083

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7083 Get It

Ventilatory Constraints in Patients With HFpEF During Exercise: Impact of Lung Size and Upper Body Adiposity
Cifci, Gizem , Brown, Daniel J., Smith, Joshua R.

Mayo Clinic

A67. COUGH, VENTILATORY CONSTRAINTS, AND NEURAL VENTILATORY CONTROL: IMPLICATIONS TO PULMONARY REHABILITATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2455-A2455

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2455 Get It

Association of Pre-pandemic High Attenuation Areas on Lung CT and COVID-19 Hospitalization and Death: The C4R Study
Kim, J. , Balte, P., Sun, Yifei , Smith, B.M. , Podolanczuk, A., Lee, J.S., Washko, G.R., Hunninghake, G.M., Regan, E.A., Woodruff, P., Ortega, Victor E. , Lynch, David A. , Laine, Andrew F. , Hoffman, E.A., Oelsner, E., Hermann, E.A. , Schwartz, David A. , Stukovsky, Karen Hinckley , Make, Barry J. , Hoffman, E.A., Barr, R. Graham

Mayo Clinic

C107. MICROBIAL RESPIRATORY INFECTIONS DISCOVERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6814-A6814

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6814 Get It

Association of CT-Assessed Dysanapsis With Interstitial Lung Abnormalities in Older Adults
Kim, J. , Anderson, Michaela R. , Hoffman, E.A., Raghu, Ganesh , Ortega, Victor E. , Woodruff, P., Tan, W.-C. , Bourbeau, J., Bossé, Ynuk , Podolanczuk, A., Berger, K., Assayag, Deborah , Manichaikul, Ani , Rich, Stephen S. , Kaner, Robert J. , Hoffman, E.A., Ohar, Jill , Tan, W.C. , Barr, R. Graham , Oelsner, Elizabeth C. , Smith, Benjamin M.

Mayo Clinic

A46. DIAGNOSIS AND MONITORING OF ILD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1746-A1746

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1746 Get It